Patents by Inventor Peter D. Senter

Peter D. Senter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PSMA ANTIBODY-DRUG CONJUGATES
    Publication number: 20210023094
    Abstract: This invention relates generally to antibody-drug conjugates (ADCs). In particular, the invention relates to ADCs which comprise an antibody or antigen-binding fragment thereof which binds to prostate-specific membrane antigen (PSMA) and is conjugated to monomethylauristatin norephedrine or monomethylauristatin phenylalanine. The antibody-drug conjugate has a PC-3™ cell to C4-2 or LNCaP™ cell selectivity of at least 250. The invention also relates, in part, to compositions of and methods of using the ADCs. The methods provided include, for example, methods for treating a PSMA-mediated disease.
    Type: Application
    Filed: July 6, 2020
    Publication date: January 28, 2021
    Applicant: PSMA Development Company, LLC
    Inventors: Dangshe Ma, Paul J. Maddon, William C. Olson, Svetlana O. Doronina, Brian E. Toki, Peter D. Senter
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20200347149
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: July 20, 2020
    Publication date: November 5, 2020
    Inventors: Svetlana O. DORONINA, Peter D. SENTER, Brian E. Toki, Toni Beth KLINE
  • Monomethylvaline compounds capable of conjugation to ligands
    Patent number: 10808039
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: October 20, 2020
    Assignee: Seattle Genetics Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Toni Beth Kline
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20190338045
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: July 10, 2019
    Publication date: November 7, 2019
    Inventors: Svetlana O. DORONINA, Peter D. SENTER, Brian E. TOKI, Toni Beth KLINE
  • Monomethylvaline compounds capable of conjugation to ligands
    Patent number: 10414826
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: September 17, 2019
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Toni Beth Kline
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20180127512
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: November 13, 2017
    Publication date: May 10, 2018
    Inventors: Svetlana O. DORONINA, Peter D. SENTER, Brian E. TOKI, Toni Beth KLINE
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20170000897
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: June 21, 2016
    Publication date: January 5, 2017
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Toni Beth Kline
  • Methods of using monomethylvaline compositions having phenylalanine carboxy modifications at the C-terminus
    Patent number: 9522194
    Abstract: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand-drug conjugates were active in vitro and in vivo in inhibiting cell proliferation and are represented by the general structure of Lv-[(LU)0-1-(D)1-4]p wherein L- is Ligand unit; LU is a Linker unit (LU); v is 1; p is an number ranging from about 1 to about 20; and D is a drug moiety having the formula: wherein the moiety —N(R9)Z1 is a phenylalanine bioisostere, wherein Z1 is —CH(R10)Z2 so that the phenylalanine bioisostere has the structure of Formula A: and wherein the substituents R2-R10, X1 and Z2 are as defined.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: December 20, 2016
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O Doronina, Toni Beth Kline, Scott Jeffrey, Peter D Senter, Damon Meyer
  • METHODS OF USING MONOMETHYLVALINE COMPOSITIONS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS
    Publication number: 20150044238
    Abstract: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand-drug conjugates were active in vitro and in vivo in inhibiting cell proliferation and are represented by the general structure of Lv-[(LU)0-1-(D)1-4]p wherein L- is Ligand unit; LU is a Linker unit (LU); v is 1; p is an number ranging from about 1 to about 20; and D is a drug moiety having the formula: wherein the moiety —N(R9)Z1 is a phenylalanine bioisostere, wherein Z1 is —CH(R10)Z2 so that the phenylalanine bioisostere has the structure of Formula A: and wherein the substituents R2-R10, X1 and Z2 are as defined.
    Type: Application
    Filed: September 30, 2014
    Publication date: February 12, 2015
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Svetlana O Doronina, Toni Beth Kline, Scott Jeffrey, Peter D Senter, Damon Meyer
  • Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
    Patent number: 8906376
    Abstract: Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions of the invention are also disclosed.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: December 9, 2014
    Assignee: Seattle Genetics, Inc.
    Inventors: Peter D. Senter, Svetlana O. Doronina, Brian E. Toki
  • Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
    Patent number: 8871720
    Abstract: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: October 28, 2014
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Toni Beth Kline, Scott Jeffrey, Peter D. Senter, Damon Meyer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20140220047
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: February 28, 2014
    Publication date: August 7, 2014
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Toni Beth Kline
  • Monomethylvaline compounds capable of conjugation to ligands
    Patent number: 8703714
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: April 22, 2014
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Toni Beth Kline
  • Monomethylvaline compounds capable of conjugation to ligands
    Patent number: 8557780
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: October 15, 2013
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120148610
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: February 15, 2012
    Publication date: June 14, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120148608
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: February 15, 2012
    Publication date: June 14, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120141510
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: February 15, 2012
    Publication date: June 7, 2012
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120141508
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: February 15, 2012
    Publication date: June 7, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120141509
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: February 15, 2012
    Publication date: June 7, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120034247
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: July 22, 2011
    Publication date: February 9, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer